Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

about

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Item

http://www.wikidata.org/entity/Q47842052

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@en

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@nl

type

Item

label

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@en

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@nl

prefLabel

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@en

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

@nl

P1476

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint

@en

P2093

Bogdan Musielak

http://www.w3.org/2001/XMLSchema#string

Ewa Rudzinska-Szostak

http://www.w3.org/2001/XMLSchema#string

Katarzyna Magiera-Mularz

http://www.w3.org/2001/XMLSchema#string

Krzysztof M Zak

http://www.w3.org/2001/XMLSchema#string

Lukasz Skalniak

http://www.w3.org/2001/XMLSchema#string

Tad A Holak

http://www.w3.org/2001/XMLSchema#string

Tryfon Zarganes-Tzitzikas

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint blockade: a common denominator approach to cancer therapy

The future of immune checkpoint therapy

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.

Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

Combination cancer immunotherapy and new immunomodulatory targets.

Development trends for human monoclonal antibody therapeutics.

P304

13732-13735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201707707

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28881104

http://www.w3.org/2001/XMLSchema#string

P932

6400216

http://www.w3.org/2001/XMLSchema#string